Showing results (151-160 of 158) with videos related to

Sort By:
Pageof 16
You have reached the last page of results.This site can display upto 158 results.
Plos One|April 15, 2022
Validation of the accuracy of the FAST™ score for detecting patients with at-risk nonalcoholic steatohepatitis (NASH) in a North American cohort and comparison to other non-invasive algorithmsTinsay A Woreta, Mark L Van Natta, Mariana Lazo, et al.
The New England Journal of Medicine|February 7, 2024
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver FibrosisStephen A Harrison, Pierre Bedossa, Cynthia D Guy, et al.
The Lancet. Gastroenterology & Hepatology|March 24, 2022
Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trialStephen A Harrison, Manal F Abdelmalek, Guy Neff, et al.
The American Journal of Gastroenterology|March 27, 2025
ALADDIN: A Machine Learning Approach to Enhance the Prediction of Significant Fibrosis or Higher in Metabolic Dysfunction-Associated Steatotic Liver DiseaseNaim Alkhouri, Terry Cheuk-Fung Yip, Laurent Castera, et al.
Lancet (London, England)|December 10, 2019
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trialZobair M Younossi, Vlad Ratziu, Rohit Loomba, et al.
Hepatology (Baltimore, Md.)|June 26, 2023
A multisociety Delphi consensus statement on new fatty liver disease nomenclatureMary E Rinella, Jeffrey V Lazarus, Vlad Ratziu, et al.
Annals of Hepatology|June 26, 2023
A multisociety Delphi consensus statement on new fatty liver disease nomenclatureMary E Rinella, Jeffrey V Lazarus, Vlad Ratziu, et al.
Journal of Hepatology|June 26, 2023
A multisociety Delphi consensus statement on new fatty liver disease nomenclatureMary E Rinella, Jeffrey V Lazarus, Vlad Ratziu, et al.
Pageof 16